In addition to Mr. Martin’s Thought Leader of the Decade Award in the Manufacturing Pillar category, Pall Corporation is associated with several other honorees in the BioProcess Awards competition. Ireland’s National Institute for Bioprocessing Research and Training (NIBRT), who Pall has partnered with on industry training efforts, was the winner in the Manufacturing Collaboration of the Decade Award. GlaxoSmithKline and Pfenex Inc. were named finalists in the Upstream Technical Application of the Decade category for their implementation of Pall’s Micro-24 scaleable, disposable 10 mL bioreactor technology (developed by MicroReactor Technologies). Mr. Martin was also a finalist for the Thought Leader of the Decade Awards in the Upstream and Downstream Pillar categories.Mr. Martin has more than 35 years of experience in microbiology and technical services, R&D, technical marketing, and industry/regulatory liaison. He has co-authored numerous PDA Technical Reports, BPSA Guides and ASTM, ISO and ASME-BPE Standards in the field. He has conducted training seminars around the world for industry and regulatory agencies including US FDA, EMA, Ireland IMB, Korea FDA, China SFDA, Japan MHLW and Australia TGA. He currently serves as Chairman of the Board of BPSA, the single-use biopharma manufacturing trade association, and is also an active member of ASME-BPE, ISPE and PDA, where he received the 2007 Distinguished Service Award. About Pall Corporation Pall Corporation ( NYSE: PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green. Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50446236&lang=en
Pall Corporation (NYSE: PLL) and its leadership team have been instrumental in the shift toward single-use manufacturing in the biopharmaceutical industry. This critical role was recognized by BioProcess International (BPI) with its announcement that Pall’s Jerold Martin was named Thought Leader of the Decade in the Manufacturing Pillar category of the magazine’s Honoring a Decade of BioProcess Awards.
Jerold Martin, Sr. Vice President for Global Scientific Affairs, Pall BioPharmaceuticals (Photo: Business Wire)The 2012 BioProcess International Awards were created to celebrate BioProcess International's 10-year anniversary and recognize the outstanding products, services, partnerships and people that have had the greatest positive impact on the “three pillars” of bioprocessing. Winners and finalists were honored by their peers last week at an awards dinner and ceremony as part of the 2012 BioProcess International Conference and Exhibition in Providence, Rhode Island. Mr. Martin, Sr. Vice President for Global Scientific Affairs, Pall BioPharmaceuticals, was recognized by the independent judging committee for his visionary leadership and advocacy efforts related to single-use biomanufacturing. He is a frequent speaker and author on the application of single-use technologies and topics related to filtration and aseptic processing. He also led the Bio-Process Systems Alliance (BPSA) trade association in developing a series of consensus best-practice guides that have become broadly accepted. “This is a well-deserved honor,” said Yves Baratelli, President, Pall Life Sciences. “Jerry was at the forefront of the bioprocessing industry’s shift toward a single-use manufacturing paradigm. He also has been an essential voice for Pall, bringing attention to our trend-setting work in single-use and disposable technologies.” Over the last 10 years, Pall has led the charge in commercializing single-use technologies that are now widely used in the development and manufacturing of biopharmaceuticals. Pall’s single-use product solutions have helped companies improve the cost of capital and add flexibility to their manufacturing operations while allowing them to be more competitive in an evolving global marketplace. Innovations from Pall include the first large scale Kleenpak™ capsule filters and sterile connectors, Allegro™ biocontainers and systems, Mustang® chromatography membranes and Cadence™ in-line concentrators. Pall and its biopharmaceutical leaders have brought clarity to the technical challenges and questions related to the use of single-use disposables in the production of biopharmaceuticals. From assisting with the qualification and validation of single-use systems to navigating regulatory requirements and addressing disposal questions, Pall experts have played a key role in the adoption of this emerging trend.